Comparison between Aptus Pharma IPO and Neptune Logitek IPO.
Aptus Pharma IPO is a SME Fixed Price IPO proposed to list at BSE SME while Neptune Logitek IPO is a SME Fixed Price proposed to list at BSE SME.
| Aptus Pharma IPO | Neptune Logitek IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Fixed Price |
| Listing At | BSE SME | BSE SME |
| Lead Managers | Interactive Financial Services Ltd. | Galactico Corporate Services Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Market-Hub Stock Broking Pvt.Ltd. | Asnani Stock Broker Pvt.Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Aptus Pharma IPO is up to ₹12.36 Cr whereas the issue size of the Neptune Logitek IPO is up to ₹44.29 Cr. The final issue price of Aptus Pharma IPO is ₹70.00 per share and of Neptune Logitek IPO is ₹126.00 per share.
| Aptus Pharma IPO | Neptune Logitek IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹65.00 per share | |
| Issue Price (Upper) | ₹70.00 per share | |
| Issue Price (Final) | ₹70.00 per share | ₹126.00 per share |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 2000 shares | 1000 shares |
| Fresh Issue Size | 17,66,000 shares | 35,15,000 shares |
| Fresh Issue Size (Amount) | up to ₹12.36 Cr | up to ₹44.29 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 17,66,000 shares | 35,15,000 shares |
| Issue Size Total (Amount) | up to ₹12.36 Cr | up to ₹44.29 Cr |
Aptus Pharma IPO opens on Sep 23, 2025, while Neptune Logitek IPO opens on Dec 15, 2025. The closing date of Aptus Pharma IPO and Neptune Logitek IPO is Sep 25, 2025, and Dec 17, 2025, respectively.
| Aptus Pharma IPO | Neptune Logitek IPO | |
|---|---|---|
| Anchor Bid Date | Sep 22, 2025 | |
| Issue Open | Sep 23, 2025 | Dec 15, 2025 |
| Issue Close | Sep 25, 2025 | Dec 17, 2025 |
| Basis Of Allotment (Tentative) | Sep 26, 2025 | Dec 18, 2025 |
| Initiation of Refunds (Tentative) | Sep 29, 2025 | Dec 19, 2025 |
| Credit of Share (Tentative) | Sep 29, 2025 | Dec 19, 2025 |
| Listing date (Tentative) | Sep 30, 2025 | Dec 22, 2025 |
| Anchor Lockin End date 1 | Oct 26, 2025 | |
| Anchor Lockin End date 2 | Dec 25, 2025 |
Aptus Pharma IPO P/E ratio is 11.29, as compared to Neptune Logitek IPO P/E ratio of 13.76.
| Aptus Pharma IPO | Neptune Logitek IPO | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Aptus Pharma Ltd.'s revenue increased by 38% and profit after tax (PAT) rose by 288% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Neptune Logitek Ltd.'s revenue increased by 48% and profit after tax (PAT) rose by 254228% between the financial year ending with March 31, 2025 and March 31, 2024.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 99.99 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 72.89 | 72.99 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 11.29 | 13.76 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹48.02 Cr. | ₹172.62 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 44.50% | 14.89% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 45.66% | 21.25% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.49 | 2.91 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹6.20 | ₹9.16 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 44.50% | 45.89% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Aptus Pharma IPO Retail Individual Investors (RII) are offered 6,20,000 shares while in Neptune Logitek IPO retail investors are offered 6,20,000 shares. Qualified Institutional Buyers (QIB) are offered 3,52,000 shares in Aptus Pharma IPO and 0 shares in Neptune Logitek IPO.
| Aptus Pharma IPO | Neptune Logitek IPO | |
|---|---|---|
| Anchor Investor Reservation | 5,28,000 shares | 0 shares |
| Market Maker Reservation | 94,000 shares | 1,85,000 shares |
| QIB | 3,52,000 shares | 0 shares |
| NII | 2,66,000 shares | 17,57,500 shares |
| RII | 6,20,000 shares | 17,57,500 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 17,66,000 shares | 35,15,000 shares |
Aptus Pharma IPO subscribed 22.27x in total, whereas Neptune Logitek IPO subscribed 1.61x.
| Aptus Pharma IPO | Neptune Logitek IPO | |
|---|---|---|
| QIB (times) | 1.24x | |
| NII (times) | 28.75x | 0.32x |
| Big NII (times) | 30.64x | |
| Small NII (times) | 24.93x | |
| RII (times) | 31.43x | 2.90x |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 22.27x | 1.61x |
